Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice

Giuseppe Boriani1*, Deirdre A. Lane2, Stephan Windecker3, Kurt Huber4, Paulus Kirchhof5,6, and Gregory Y.H. Lip2

1Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy; 2University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK; 3Department of Cardiology, Bern University Hospital, Bern, Switzerland; 43rd Dept of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, A-1160 Vienna, Austria; 5Centre for Cardiovascular Sciences, University of Birmingham and SWBH NHS Trust, Birmingham, UK; and 6Department of Cardiology and Angiology, Univerita¨tsklinikum Münster, D-48149 Münster, Germany

Online publish-ahead-of-print 12 February 2015

This editorial refers to ‘Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).’ by Lip et al., on page 3155–3179.

In a series of clinical scenarios decision making on the most appropriate treatments to be applied in an individual patient may become very difficult, in view of the risk of treatment-related adverse events that have to be balanced against the benefits that a specific medication or intervention may offer.

When a clinician has to decide on use of antithrombotic drugs in the setting of a patient affected by atrial fibrillation (AF) experiencing an acute coronary syndrome (ACS), the difficult task is avoiding thrombotic events (stroke prevention, recurrent cardiac ischaemia in an ACS setting, stent thrombosis if one is implanted) against the risk of haemorrhage when oral anticoagulant (OAC) is combined with antiplatelet therapy. This is really challenging, like the navigation between Scylla and Charybdis in the Strait of Messina, between Calabria and Sicily in Italy.1

In a patient with AF the need to decide on antithrombotic therapy is common in clinical practice, whereby according to current guidelines2 an indication for OACs can be present in over 80% of AF patients; however, 30% of them having vascular disease and around 20% requiring a percutaneous cardiovascular intervention (PCI) at some stage.3 On the other hand, previously undetected AF often complicates an ACS in up to 20% of patients.4

Many physicians, with different specialities and professional tasks get ‘involved’ in the management of a patient affected by AF (Figure 1), looking at this patient from variable perspectives, with need to coordinate decisions and actions with some of the colleagues, in a team-work that nowadays becomes necessary in order to guarantee the highest levels of care. For all of these colleagues, decision making and patient management in the setting of patients with AF and ACS or invasive cardiovascular interventions is particularly demanding and complex.

The joint consensus document of the European Society of Cardiology (ESC) Working Group on Thrombosis, European Heart Rhythm Association, European Association of Percutaneous Cardiovascular Interventions, and European Association of Acute Cardiac Care, endorsed by Heart Rhythm Society and Asia-Pacific Heart Rhythm Society has been prepared with the aim to help decision making in this complex setting, where more frequently than in other settings cohort studies and registries contribute to generation of recommendations, in view of relative paucity of randomized clinical trials.3

Performing a PCI and managing appropriately the antithrombotic regimen is a task with the typical characteristics of ‘complex interventions’, in view of the multiple interacting components, the implications in terms of organization, of care, and the relevance and variability of outcomes. Therefore, the European consensus document has important implications in terms of organization of care.
and should be an important reference for organizing networks for patient referral and patient follow-up, whereby interventional cardiologists, clinical cardiologists, electrophysiologists, and all the other physicians involved in the care of AF patients should coordinate their work, in an attempt to obtain such synergistic effects that these types of clinical scenarios may request.

In such situations, decision making has to be based on a comprehensive patient-centred and individualized approach, whereby all the knowledge from scientific evidence, summarized in consensus guidelines and consensus documents, has to be combined with individual clinical assessment, with the important aid of a series of user-friendly risk scores that appropriately depict the individual risk, in terms of stroke or bleeding hazards, as well as in terms of likelihood of appropriate anticoagulation use.

Individualization and personalization of care is actually needed, both on the side of physicians taking care of medical therapy (antiplatelet drugs, or OAC, whether non-vitamin K antagonist or vitamin K antagonist (VKA)) and on the side of interventional cardiologists (choice of access, choice of stent, etc.), thus reaching an agreement also on the optimal duration of combined antithrombotic treatment.

The European consensus document proposes a series of specific concepts that carry important practical implications:

1. Non-vitamin K antagonist OACs (NOACs) and VKA can be used when an OAC is recommended;
2. If a VKA is used in combination with antiplatelet agents, international normalized ratio (INR) should ideally be controlled between 2.0 and 2.5, with a good time in therapeutic range (>70%, which may be difficult to achieve);
3. If a NOAC is used in combination with antiplatelet agents, the respective lower tested dose (dabigatran 110 mg twice a day, rivaroxaban 15 mg once a day, apixaban 2.5 mg twice a day) should be used;
4. New generation P2Y12-inhibitors (prasugrel, ticagrelor) should not be used in antithrombotic combination therapy with anticoagulants before specific studies validate their role in combined therapy.

Figure 2, from the Consensus document, shows how to reach a final decision on the most appropriate antithrombotic treatment, as a result of a multi-staged approach that considers stroke risk, bleeding risk, clinical setting (ACS or stable coronary artery disease) and type of intervention performed (using drug-eluting stent or bare-metal stent), with different potential choices according to needed intensity of antithrombotic therapy and time horizon (triple or dual therapy including oral anticoagulants, dual antiplatelet therapy, oral anticoagulants alone). Where VKA is used, good quality INR control is necessary, aiming for a time in therapeutic range >70%.

As the document reports, many areas of uncertainty remain and current recommendations are based on expert consensus and/or derived from extrapolation of data from patients in sinus rhythm, observational studies, subgroup analyses, and a few smaller controlled trials. This is particularly the case of the NOACs, for which there is growing interest but limited evidence available, until the completion of ongoing trials. This is, particularly, the case given the potential for increased gastrointestinal bleeds with some NOACs, probably accentuated when the NOAC is combined with an antiplatelet drug.

The best therapeutic solution, considering the competing risks of ischaemic stroke, bleeding, recurrent coronary events, and stent thrombosis surely requires some degree of personalized management, which could substantially benefit from a team work among all the actors involved.

In these complex settings, it is quite important to have ‘reality check’ of what happens in ‘real world’ clinical practice. The Euro Observational Research Programme Atrial Fibrillation (EORP-AF) Pilot Registry, promoted by the European Society of Cardiology, offers the possibility to evaluate the full contemporary picture of AF patients across Europe and of antithrombotics use, according to current guidelines. The EORP-Pilot phase collected information, on all patients presenting to cardiologists as in- or out-patients with an electrocardiogram documented diagnosis of AF in the year prior to enrolment, and 3119 patients were collected from February 2012 to March 2013. Among these patients, enrolled in nine ESC member Countries, a history of coronary artery disease was present in around 48% of patients, without significant regional differences. Coronary artery disease was associated with a significantly reduced use of OAC alone, lower prescription of NOACs and a significantly increased prescription of antiplatelet drugs alone or in combination with OAC.

According to these data, coming from ‘real world’ clinical practice, it is clear that coronary artery disease, in general, markedly affects prescription and management of antithrombotic treatment in AF patients, despite the potential for high bleeding. It is expected that when the natural history of coronary artery disease evolves to an acute phase, i.e. an ACS, with need for new treatments and PCIs, the difficulty of decision making in such a complex and challenging scenario will be magnified. For these reasons, we think that all the cardiologists and particularly the electrophysiologists taking care of AF patients will benefit from the availability of these updated, clinically oriented recommendations. In this evolving scenario growing interest is developing on NOACs, whose uptake in AF patients is increasing, but with need for more data on the specific setting of ACS, some trials are ongoing.

As for all the medical or interventional treatments with high impact on practices, organization of care and costs, the implications and consequences of recommended strategies should be object of analysis.
Non-valvular atrial fibrillation

- **CHA\(_2\)DS\(_2\)-VASc = 1**
  - Low to intermediate (e.g. HAS-BLED = 0–2)
  - Stable CAD
  - ACS

- **CHA\(_2\)DS\(_2\)-VASc ≥ 2**
  - High (e.g. HAS-BLED ≥ 3)
  - Stable CAD
  - ACS

**STEP 1 — Stroke risk**

**STEP 2 — Bleeding risk**

- **HAS-BLED = 0–2**
- **HAS-BLED ≥ 3**

**STEP 3 — Clinical setting**

If PCI is performed

- **Triple or dual therapy***
  - Monotherapy***

**STEP 4 — Antithrombotic therapy**

- **Oral anticoagulation**
- **Aspirin 75–100 mg daily**
- **Clopidogrel 75 mg daily**

**Figure 2** Choice of antithrombotic therapy, including combination strategies of oral anticoagulation (O), aspirin (A), and/or clopidogrel (C). For Step 4, background colour and gradients reflect the intensity of antithrombotic therapy (i.e. dark background colour = high intensity; light background colour = low intensity). Solid boxes represent recommended drugs. Dashed boxes represent optional drugs depending on clinical judgement. New generation drug-eluting stent is generally preferable over bare-metal stent, particularly in patients at low bleeding risk (HAS-BLED 0–2). When vitamin K antagonists are used as part of triple therapy, international normalized ratio should be targeted at 2.0–2.5 and the time in the therapeutic range should be > 70%. *Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients. **Aspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e. oral anticoagulation plus single antiplatelet). ***Dual therapy with oral anticoagulation and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at very high risk of coronary events. ACS, acute coronary syndromes; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention. Reproduced with permission from: Lip GY, et al.
and re-evaluation, in accordance with the path of Health Technology Assessments. National and international registries or other targeted initiatives will be of help to give the appropriate feedback to clinicians, regulators and policy-makers.

Conflict of interest: G.B. received speaker fees (small amount) from Boehringer, Boston, Medtronic and St. Jude. S.W. received speaker fees from Abbott, Astra Zeneca, Eli Lilly, Medtronic, and also research grants to the Institution from Biotronik and St. Jude. D.L. received educational grants (investigator-initiated) from Bayer Healthcare and Boehringer Ingelheim. D.L. is a speaker bureau for Boehringer Ingelheim and Bristol Myers Squibb/Pfizer. K.H. received speaking fees from Bayer, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim (> $10,000 K) and Daiichi Sankyo. P.K. received consulting fees and honoraria from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Daiichi-Sankyo, German Cardiac Society—Akademie, Johnson & Johnson, Medtronic, Pfizer, Sanofi, Servier. Research grants to the Institution from Bristol-Myers Squibb (BMS)/Pfizer, Cardiovascular Therapeutics, Daiichi Sankyo, Sanofi, St. Jude Medical, German Federal Ministry for Education and Research (BMBF), Fondation Leducq, German Research Foundation (DFG), European Union (EU), British Heart Foundation (BHF). G.L. is a consultant for Bayer Healthcare, Astellas, Merck, AstraZeneca, Sanofi Aventis, Bristol-Myers Squibb/Pfizer and Boehringer Ingelheim. Speaker bureaus for Bayer, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim and Sanofi Aventis.

References